Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: RECTIV

« Back to Dashboard

Rectiv is a drug marketed by Forest Labs Inc and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug.

The generic ingredient in RECTIV is nitroglycerin. There are thirty-seven drug master file entries for this compound. Eighteen suppliers are listed for this compound. There are three tentative approvals for this compound. Additional details are available on the nitroglycerin profile page.

Summary for Tradename: RECTIV

Patents:1
Applicants:1
NDAs:1
Suppliers: see list2

Pharmacology for Tradename: RECTIV

Ingredient-typeNitrates
Drug ClassNitrate Vasodilator
Physiological EffectVasodilation

Clinical Trials for: RECTIV

Nitroglycerin in Non-small Cell Lung Cancer
Status: Recruiting Condition: Non Small Cell Lung Cancer (NSCLC)

Radial Artery Dilation Study: The Effect of Topical Administration of Nitroglycerin and Lidocaine Versus Lidocaine Alone of the Radial Artery Diameter
Status: Completed Condition: Healthy

Treatment of Suspected Cholelithiasis With Nitroglycerin
Status: Not yet recruiting Condition: COLIC; BILIARY TRACT DISEASES

GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy
Status: Recruiting Condition: Prostate Cancer

Investigation Into the Role of GTN & RIPC in Cardiac Surgery
Status: Not yet recruiting Condition: Myocardial Reperfusion Injury

MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects
Status: Completed Condition: Healthy

GOT-IT Trial: Glyceryl Trinitrate for Retained Placenta
Status: Recruiting Condition: Retained Placenta.

The Use of Glyceryl Trinitrate Patches in Arteriovenous Fistulas
Status: Not yet recruiting Condition: Renal Failure

The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women
Status: Recruiting Condition: Contraception; Pain

Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon
Status: Completed Condition: Raynaud's Phenomenon

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs Inc
RECTIV
nitroglycerin
OINTMENT;INTRA-ANAL021359Jun 21, 2011RXYes7,189,761<disabled>Y<disabled>
Forest Labs Inc
RECTIV
nitroglycerin
OINTMENT;INTRA-ANAL021359Jun 21, 2011RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc